HolderBook

Decheng Capital Management III (Cayman), LLC

Reported holdings as of Q3 2023, from 7 quarterly filings.

This filer last reported in Q3 2023; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1747821
Reported value
$299.6M
Positions
26
Top 10 weight
79.2%
Filed
2023-12-12
Days after quarter end
73

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
ALPINE IMMUNE SCIENCES INCALPN$76.8M6,708,28825.63%-newNEW
ZENTALIS PHARMACEUTICALS INCZNTL$42.1M2,099,58314.06%-4.52pp6qHELD
AURA BIOSCIENCES INCAURA$18.2M1,163,1236.09%+4.95pp7q+296.5%+$13.6M
ROIVANT SCIENCES LTDROIV$17.0M1,459,7005.69%-newNEW
ACELYRIN INCSLRN$15.7M1,548,3175.26%-4.94pp2qHELD
ARCUS BIOSCIENCES INCRCUS$15.6M869,7905.21%-0.33pp7qHELD
10X GENOMICS INCTXG$14.8M359,5544.95%-1.35pp7qHELD
ARGENX SEARGX$13.5M27,4294.50%+1.15pp5qHELD
PACIFIC BIOSCIENCES CALIF INPACB$12.2M1,463,8724.08%-2.03pp7qHELD
ILLUMINA INCILMN$11.1M80,8593.70%-1.05pp7qHELD
LANTHEUS HLDGS INCLNTH$9.9M142,1963.30%-newNEW
HORIZON THERAPEUTICS PUB LHZNP$9.1M78,9003.05%+0.50pp6qHELD
PHATHOM PHARMACEUTICALS INCPHAT$8.8M850,0002.94%-0.88pp2qHELD
IMMUNOGEN INCIMGN$6.6M415,8802.20%-newNEW
SEAGEN INCSGEN$4.9M23,0141.63%-newNEW
CUE HEALTH INCHLTHQ$4.0M8,980,9091.32%+0.28pp7qHELD
BEYONDSPRING INCBYSI$4.0M4,958,1431.32%-newNEW
TERNS PHARMACEUTICALS INCTERN$3.6M714,2851.20%-0.76pp7qHELD
EQUILLIUM INCEQ$3.3M4,447,3081.10%+0.05pp7qHELD
WHITEHAWK THERAPEUTICS INCWHWK$2.5M526,3290.85%-0.28pp7qHELD
ATRICURE INCATRC$2.0M46,2590.68%-newNEW
SCYNEXIS INCSCYX$1.3M555,5550.42%-0.09pp7qHELD
MERSANA THERAPEUTICS INC COMMRSN$1.1M904,2680.38%-0.55pp7qHELD
PYXIS ONCOLOGY INCPYXS$650.4K326,8100.22%-newNEW
GENEDX HOLDINGS CORPWGS$377.1K103,6040.13%-newNEW
ADICET BIO INCACET$274.3K200,2010.09%-0.29pp7q-60.4%-$418.5K

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 58.5%Other sectors 0.8%Not classified 40.7%
 
SectorValueShare
Biotech & Pharma$175.4M58.5%
Other sectors$2.4M0.8%
Not classified$121.9M40.7%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q3 2023$299.6M26911879.2%73
Q2 2023$318.8M25513484.9%28
Q1 2023$247.9M24211483.2%40
Q4 2022$267.2M26211280.2%40
Q3 2022$275.8M26341279.0%39
Q2 2022$263.7M25200183.1%32
Q1 2022$326.3M24000082.7%40

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.